TB006 for Parkinson's Disease

TB006 for Parkinson's Disease

Overview

TB006 is an investigational Galectin-3 targeting monoclonal antibody being developed by TrueBinding Inc. as a potential disease-modifying therapy for Parkinson's Disease (PD). The therapy received FDA IND clearance and is currently undergoing a Phase 2A clinical trial (NCT06773962) evaluating safety and efficacy in patients with early to mild Parkinson's Disease [1].

Galectin-3 is a β-galactoside-binding lectin that plays a critical role in inflammatory responses and has been increasingly recognized as a key contributor to neuroinflammation in neurodegenerative diseases. TB006 represents a novel approach to PD treatment by targeting the underlying inflammatory pathophysiology rather than solely addressing symptoms [2].

Mechanism of Action

Galectin-3 Biology

Galectin-3 (Gal-3) is a member of the galectin family of carbohydrate-binding proteins characterized by their affinity for β-galactosides. Unlike other galectins, Galectin-3 possesses a unique N-terminal proline-rich tail that enables it to form higher-order oligomers and function as a versatile signaling molecule [3].

Key aspects of Galectin-3 in neurodegeneration:

TB006 for Parkinson's Disease

Overview

TB006 is an investigational Galectin-3 targeting monoclonal antibody being developed by TrueBinding Inc. as a potential disease-modifying therapy for Parkinson's Disease (PD). The therapy received FDA IND clearance and is currently undergoing a Phase 2A clinical trial (NCT06773962) evaluating safety and efficacy in patients with early to mild Parkinson's Disease [1].

Galectin-3 is a β-galactoside-binding lectin that plays a critical role in inflammatory responses and has been increasingly recognized as a key contributor to neuroinflammation in neurodegenerative diseases. TB006 represents a novel approach to PD treatment by targeting the underlying inflammatory pathophysiology rather than solely addressing symptoms [2].

Mechanism of Action

Galectin-3 Biology

Galectin-3 (Gal-3) is a member of the galectin family of carbohydrate-binding proteins characterized by their affinity for β-galactosides. Unlike other galectins, Galectin-3 possesses a unique N-terminal proline-rich tail that enables it to form higher-order oligomers and function as a versatile signaling molecule [3].

Key aspects of Galectin-3 in neurodegeneration:

• Inflammatory Signaling: Galectin-3 acts as a damage-associated molecular pattern (DAMP) molecule, activating immune cells including microglia and astrocytes
• Microglial Activation: Galectin-3 is specifically upregulated in activated microglia and serves as a marker of neuroinflammatory states
• Cytokine Regulation: Galectin-3 modulates the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
• NLRP3 Inflammasome: Galectin-3 interacts with and potentiates NLRP3 inflammasome activation in myeloid cells

TB006 Therapeutic Approach

TB006 is a monoclonal antibody designed to bind and neutralize Galectin-3, thereby reducing neuroinflammation and potentially slowing or halting disease progression in Parkinson's Disease [1].

Mechanistic Pathway:

TrueBinding Inc. - Company Background

Corporate Profile

TrueBinding is a biotechnology company headquartered in Santa Clara, California, focused on developing therapeutics that target the biology of aging through Galectin-3 neutralization [1]:

• Founded: California-based biotech with focus on aging-related diseases
• Mission: To resolve chronic inflammaging through Galectin-3 targeting
• Location: 4701 Patrick Henry Drive, Building 21, Santa Clara, CA 95054
• Contact: info@truebinding.com | 650-847-1117

Pipeline Overview

TrueBinding's pipeline extends beyond Parkinson's Disease:

| Indication | Status | Approach |
|------------|--------|----------|
| Alzheimer's Disease | Expanded Access Program | Galectin-3 neutralization |
| Parkinson's Disease | Phase 2A (NCT06773962) | Galectin-3 neutralization |
| Glioblastoma | Partnership with UCSF | Galectin-3 neutralization |

The company's research has been published in peer-reviewed journals including Neuro-Oncology (November 2025) [1].

Clinical Development

Phase 2A Trial (NCT06773962)

Trial Overview:

• Identifier: NCT06773962
• Phase: Phase 2A
• Status: Recruiting
• Sponsor: TrueBinding, Inc.
• Design: Multi-center, randomized, double-blind, placebo-controlled
• Population: Early to mild Parkinson's Disease patients
• Setting: Multiple centers in the United States

Outcome Measures:

The trial employs standardized Parkinson's Disease rating scales including:

• MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)
• Safety and tolerability assessments
• Biomarker evaluations

Rationale for Galectin-3 Targeting in PD

The selection of Galectin-3 as a therapeutic target in Parkinson's Disease is supported by substantial evidence:

Genetic Evidence:

• GWAS studies have identified inflammatory pathways in PD susceptibility
• Galectin-3 polymorphisms associated with inflammatory disease risk

• Elevated Galectin-3 expression in PD animal models
• Galectin-3 deficiency associated with reduced neuroinflammation
• Microglial Galectin-3 required for optimal inflammatory responses

• Increased Galectin-3 in post-mortem PD brain tissue
• Galectin-3 in cerebrospinal fluid as potential biomarker
• Correlation between Galectin-3 levels and disease severity

Therapeutic Implications

Disease Modification vs. Symptomatic Treatment

TB006 represents a fundamentally different approach compared to conventional PD therapies:

| Approach | Current Therapies | TB006 |
|----------|-------------------|-------|
| Mechanism | Dopamine replacement | Anti-inflammatory |
| Goal | Symptom management | Disease modification |
| Target | Motor symptoms | Underlying pathology |
| Long-term | Wearing off, dyskinesias | Potential to slow progression |

Competitive Landscape

TB006 enters a competitive Parkinson's disease modification field:

• LRRK2 inhibitors: DNL151/BIIB122 (Biogen/Denali)
• GBA therapies: Gene therapy approaches (Voyager)
• Alpha-synuclein targeting: Antibodies, oligomer blockers, ASO
• Neuroprotective agents: Inosine, GLP-1 agonists

Challenges and Considerations

Connection to Alzheimer's Disease

TrueBinding is also developing TB006 for Alzheimer's Disease and related dementias through an Expanded Access Program. The shared mechanism of neuroinflammation in both AD and PD provides rationale for investigating Galectin-3 targeting across neurodegenerative conditions [1].

Galectin-3 involvement in Alzheimer's Disease:

• Amyloid plaque-associated inflammation
• Tau pathology modulation
• Microglial activation in AD brain

Research and References

Primary Sources

Key Publications

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Microglia in Neurodegeneration](/entities/microglia)
• [Galectin-3 Biology](/entities/galectin-3)
• [Parkinson's Disease Clinical Trials Index](/clinical-trials/parkinsons-disease)
• [Disease-Modifying Therapies for PD](/therapeutics/disease-modifying-therapies-parkinsons)

External Resources

• [TrueBinding Official Website](https://www.truebinding.com)
• [ClinicalTrials.gov - TB006 PD Trial](https://clinicaltrials.gov/study/NCT06773962)
• [Parkinson's Foundation](https://www.parkinson.org/)
• [Michael J. Fox Foundation](https://www.michaeljfox.org/)

Pathway Diagram